1800 244 735

Helpline (02) 9874 9777

ROCHE HD DRUG TRIAL ANNOUNCED FOR SYDNEY

The Huntington Disease Service at Westmead Hospital has been approved to participate in a new drug trial, called Generation HD1. This study tests a Huntingtin-lowering (also known as gene silencing) agent developed by IONIS, and the trial will be run by a company called Roche. The study involves lumbar punctures, MRI scans, assessments and questionnaires.

The main goal of Generation HD1 is to compare the effects, good and/or bad, of RO7234292 against placebo, in study participants with HD. Participants must be between the ages of 25-65, have early stage Huntington Disease, and meet additional criteria. It is expected the study will involve 660 people with HD worldwide.

If you would like more information, you can call Westmead on 0456 740 612. The phone will be monitored on Mondays and Thursdays. Please leave a message if we cannot answer when you call.

Huntington’s NSW ACT, and the Huntington Disease Service at Westmead will continue to provide updates on HD research through the Huntington’s NSW ACT website.

Latest News and Stories

donate scene cartoon

We are recruiting – Support Services Administrator

Published date: 2 February, 2023

We have created a new position for an enthusiastic and committed person wanting to be part of an inclusive and supportive team in a growing NDIS specialist business and specialised programs, supporting people living with Huntington’s disease (HD) and their families. In this part-time role you will be responsible for providing administration support to a ... Read more

CEO announcement for Huntington’s Australia

Published date: 16 January, 2023

Following the recent announcement about State Association memberships agreeing to proceed with a national merger, Huntington’s Australia (HA) has appointed a new CEO to lead the new association. Lenni Duffield, from Huntington’s WA, has been unanimously endorsed by the HA Board as the inaugural CEO of Huntington’s Australia. Lenni has held senior roles and provided ... Read more

Members have agreed to merge into a new, single entity, Huntington’s Australia

Published date: 6 December, 2022

We’ve got some great news to share! Members of five State and Territory organisations (Queensland, NSW ACT, Tasmania, SA&NT and WA) have agreed to merge into a new, single entity, Huntington’s Australia (HA). We are all very excited about the opportunities this will provide to the Huntington’s community. The merger will bring together five associations ... Read more
HD news image

HD News Spring 2022

Published date: 22 November, 2022

Download your copy of HD News Spring edition by clicking on the link. Some of the highlights in this edition are: Information on the proposed merger Growth of our NDIS team Walk 4 Hope wrap up Youth Connection program update and some exciting news We hope that you enjoy this edition of HD News. If you ... Read more

Awarded for the Association Turnaround of the Year

Published date: 10 November, 2022

The Association Awardsᵀᴹ recognise excellence and accomplishment by associations and outstanding individuals. In addition to recognition, the process of nominating for an Award will be a worthwhile experience as it will encourage associations to consider the factors that make a successful association, turnaround or campaign.
APDA logo

APDA – The Good, The Bad & The Hack

Published date: 10 October, 2022

Huntington's NSW ACT is a member of The Accessible Product Design Alliance (APDA), which is a group of not-for-profit consumer health organisations working together to represent people with chronic conditions who are significantly impacted by inaccessible products and packaging. This campaign aims for those living with a disability to share their experience of different products to raise awareness of accessible and inaccessible experiences, support others to make their lives easier and help us educate product and packaging manufactures about what they need to improve.